Prof. Dr. Hubert Löwenheim

Hubert Löwenheim is Medical Director of the ENT University Clinic in Tübingen and Principal Investigator of “Regenerative Biology Group”. He has extensive experience in the field of regenerative hearing loss therapies both scientifically and clinically. He was the first describing the involvement of cell cycle regulators esp. p27Kip1 in the proliferation and differentiation of hair cells and supporting cells in the cochlea. In 1998, based on these discoveries he co-founded the company Otogene AG in Tübingen and its subsidiary Otogene Inc. in Seattle with the aim to identify an inhibitor of p27Kip1 as regenerative drug. Hubert Löwenheim received his MD from Goethe University, Frankfurt am Main and trained in Otorhinolaryngology at the University of Tübingen. His doctoral degree from Goethe University is in auditory physiology, his Habilitation degree from Tübingen University is in auditory regenerative biology. His clinical focus is in Otology & Neurootology. He has published over 50 scientific articles in the area of hearing research.

EMC microcollections GmbH (Prof. Dr. Karl-Heinz Wiesmüller)

Karl-Heinz Wiesmüller is CEO and co-founder of EMC microcollections GmbH. He has more than 20 years experience in combinatorial chemistry, expertise in peptide and lipopeptide synthesis and in synthetic vaccine development and immunochemistry documented in more than 170 original publications in peer-reviewed journals. Prior to his assignment at EMC he was Head of Libraries and Screening at EVOTEC BioSystems GmbH, Hamburg, and Leader of the Department of Biochemistry at the Natural & Medical Science Institute in Reutlingen. He holds a Habilitation degree in biochemistry, and doctoral degree (Dr. rer. Nat.) from the University of Tübingen where he is currently teaching as Professor of Biochemistry.



Boehringer Ingelheim Venture Fund

Boehringer LogoBIVF is the venture arm of the pharmaceutical company Boehringer Ingelheim GmbH the largest family-owned pharma corporation worldwide. The mission of BIVF is to invest in biotech companies working on groundbreaking innovative therapeutic approaches outside of BI’s core indication areas.